|
G |
EGF |
epidermal growth factor |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] |
CTD |
PMID:22689575 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
|
G |
ACE |
angiotensin I converting enzyme |
decreases expression increases expression multiple interactions |
ISO |
goralatide results in decreased expression of ACE mRNA goralatide results in increased expression of ACE mRNA [BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA] |
CTD |
PMID:20096676 PMID:33007385 |
|
NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] |
CTD |
PMID:33007385 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein] goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein] ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AGTR1 |
angiotensin II receptor type 1 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008
|
|
G |
BDKRB1 |
bradykinin receptor B1 |
multiple interactions affects abundance |
ISO |
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide BDKRB1 protein affects the abundance of goralatide |
CTD |
PMID:20096676 |
|
NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
COL3A1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
|
|
G |
GLI1 |
GLI family zinc finger 1 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr12:57,459,785...57,472,268
Ensembl chr12:57,459,785...57,472,268
|
|
G |
GLI2 |
GLI family zinc finger 2 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 2:120,735,868...120,992,653
Ensembl chr 2:120,735,623...120,992,653
|
|
G |
GLI3 |
GLI family zinc finger 3 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:41,960,949...42,264,268
Ensembl chr 7:41,960,949...42,264,100
|
|
G |
MAS1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 6:159,888,787...159,917,447
Ensembl chr 6:159,890,988...159,917,447
|
|
G |
PTCH1 |
patched 1 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 9:95,442,980...95,516,971
Ensembl chr 9:95,442,980...95,517,057
|
|
G |
SHH |
sonic hedgehog signaling molecule |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:155,799,980...155,812,463
Ensembl chr 7:155,799,980...155,812,463
|
|
G |
SMO |
smoothened, frizzled class receptor |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:129,188,633...129,213,545
Ensembl chr 7:129,188,633...129,213,545
|
|
G |
VIM |
vimentin |
multiple interactions |
ISO |
goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] |
CTD |
PMID:33007385 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
|
G |
SLCO4C1 |
solute carrier organic anion transporter family member 4C1 |
increases export |
EXP |
SLCO4C1 protein results in increased export of Homoarginine |
CTD |
PMID:30865704 |
|
NCBI chr 5:102,233,986...102,296,284
Ensembl chr 5:102,233,986...102,296,284
|
|
|
G |
ACE |
angiotensin I converting enzyme |
decreases activity |
EXP |
Lisinopril analog results in decreased activity of ACE protein |
CTD |
PMID:22200082 |
|
NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
increases expression multiple interactions increases activity |
ISO |
Lisinopril results in increased expression of ACE2 mRNA ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)] Lisinopril results in increased activity of ACE2 protein |
CTD |
PMID:15897343 PMID:16221218 PMID:27649628 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein] Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein] |
CTD |
PMID:23060470 PMID:31710167 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
AGT |
angiotensinogen |
decreases expression multiple interactions affects metabolic processing decreases secretion increases secretion affects response to substance increases expression |
EXP ISO |
Lisinopril results in decreased expression of AGT protein [[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)] Lisinopril results in decreased secretion of AGT protein Lisinopril results in increased secretion of AGT protein alternative form [Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA AGT gene alternative form affects the susceptibility to Lisinopril Lisinopril results in increased expression of AGT mRNA |
CTD |
PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 PMID:27649628 More...
|
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
Lisinopril results in decreased expression of BCL2 |
CTD |
PMID:10075388 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CD2AP |
CD2 associated protein |
multiple interactions |
ISO |
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] |
CTD |
PMID:16636307 |
|
NCBI chr 6:47,477,789...47,627,263
Ensembl chr 6:47,477,789...47,627,263
|
|
G |
EDN1 |
endothelin 1 |
decreases secretion |
EXP |
Lisinopril results in decreased secretion of EDN1 protein |
CTD |
PMID:19079593 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
GH1 |
growth hormone 1 |
multiple interactions |
ISO |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] |
CTD |
PMID:20051877 |
|
NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] |
CTD |
PMID:19225054 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396
|
|
G |
HLA-G |
major histocompatibility complex, class I, G |
affects expression |
EXP |
Lisinopril affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125
|
|
G |
HPSE |
heparanase |
multiple interactions |
ISO |
[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] |
CTD |
PMID:19429930 |
|
NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153
|
|
G |
IGFBP1 |
insulin like growth factor binding protein 1 |
increases expression |
EXP |
Lisinopril results in increased expression of IGFBP1 protein |
CTD |
PMID:9663927 |
|
NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] |
CTD |
PMID:20051877 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] |
CTD |
PMID:23060470 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] |
CTD |
PMID:20051877 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPHS1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions |
ISO |
Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] |
CTD |
PMID:16636307 PMID:19293598 |
|
NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287
|
|
G |
NPHS2 |
NPHS2 stomatin family member, podocin |
multiple interactions |
ISO |
Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] |
CTD |
PMID:16636307 |
|
NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952
|
|
G |
NPPA |
natriuretic peptide A |
decreases expression |
EXP |
Lisinopril results in decreased expression of NPPA protein |
CTD |
PMID:8393685 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
REN |
renin |
increases expression multiple interactions |
EXP ISO |
Lisinopril results in increased expression of REN protein [Lisinopril co-treated with Losartan] results in increased expression of REN mRNA Lisinopril results in increased expression of REN mRNA |
CTD |
PMID:2550029 PMID:8915971 PMID:16221218 |
|
NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] |
CTD |
PMID:20051877 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] |
CTD |
PMID:19293598 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein] |
CTD |
PMID:34227456 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein] |
CTD |
PMID:30896085 PMID:34227456 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BDNF |
brain derived neurotrophic factor |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein] |
CTD |
PMID:34227456 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein] |
CTD |
PMID:30896085 PMID:34227456 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP6 |
caspase 6 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein] |
CTD |
PMID:34227456 |
|
NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein] |
CTD |
PMID:34227456 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein] |
CTD |
PMID:20369241 PMID:30896085 PMID:34227456 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA] |
CTD |
PMID:35099105 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
E2F1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA] |
CTD |
PMID:27496854 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions affects binding increases activity |
EXP |
Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein] royal jelly results in increased activity of ESR1 protein |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions affects binding |
EXP |
Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein] |
CTD |
PMID:34227456 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein] |
CTD |
PMID:18981581 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
ISO |
royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA] royal jelly results in decreased expression of MYC mRNA royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA] |
CTD |
PMID:27496854 PMID:35099105 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein] |
CTD |
PMID:34227456 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] |
CTD |
PMID:30896085 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein] |
CTD |
PMID:34227456 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
TFF1 |
trefoil factor 1 |
increases expression |
EXP |
royal jelly results in increased expression of TFF1 mRNA |
CTD |
PMID:15946813 |
|
NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] |
CTD |
PMID:30896085 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
EXP ISO |
royal jelly results in increased expression of VEGFA mRNA |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|